

Malin Hultcrantz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6724055/publications.pdf>

Version: 2024-02-01

146
papers

4,067
citations

117453

34
h-index

133063

59
g-index

150
all docs

150
docs citations

150
times ranked

5007
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. <i>Haematologica</i> , 2015, 100, 107-113.	1.7	356
2	Chronic Immune Stimulation Might Act As a Trigger for the Development of Acute Myeloid Leukemia or Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2011, 29, 2897-2903.	0.8	239
3	Treatment-Related Risk Factors for Transformation to Acute Myeloid Leukemia and Myelodysplastic Syndromes in Myeloproliferative Neoplasms. <i>Journal of Clinical Oncology</i> , 2011, 29, 2410-2415.	0.8	215
4	Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008. <i>Journal of Clinical Oncology</i> , 2011, 29, 2514-2520.	0.8	183
5	Patterns of Survival Among Patients With Myeloproliferative Neoplasms Diagnosed in Sweden From 1973 to 2008: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2995-3001.	0.8	182
6	Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms. <i>Annals of Internal Medicine</i> , 2018, 168, 317.	2.0	177
7	Estrogen and hearing: a summary of recent investigations. <i>Acta Oto-Laryngologica</i> , 2006, 126, 10-14.	0.3	167
8	Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1685-1717.	2.3	138
9	Risk and Cause of Death in Patients Diagnosed With Myeloproliferative Neoplasms in Sweden Between 1973 and 2005: A Population-Based Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 2288-2295.	0.8	106
10	Ear and hearing problems in 44 middle-aged women with Turner's syndrome. <i>Hearing Research</i> , 1994, 76, 127-132.	0.9	91
11	Dramatically improved survival in multiple myeloma patients in the recent decade: results from a Swedish population-based study. <i>Haematologica</i> , 2018, 103, e412-e415.	1.7	87
12	Prevalence of myeloma precursor state monoclonal gammopathy of undetermined significance in 12372 individuals 10-49 years old: a population-based study from the National Health and Nutrition Examination Survey. <i>Blood Cancer Journal</i> , 2017, 7, e618-e618.	2.8	82
13	Revealing the Impact of Structural Variants in Multiple Myeloma. <i>Blood Cancer Discovery</i> , 2020, 1, 258-273.	2.6	81
14	NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 8-19.	2.3	80
15	Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial. <i>Blood</i> , 2018, 132, 959-959.	0.6	71
16	Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities. <i>Nature Communications</i> , 2021, 12, 1861.	5.8	68
17	Second malignancies in patients with myeloproliferative neoplasms: a population-based cohort study of 9379 patients. <i>Leukemia</i> , 2018, 32, 2203-2210.	3.3	64
18	Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2021, 7, 862.	3.4	63

#	ARTICLE	IF	CITATIONS
19	Turner's syndrome and hearing disorders in women aged 16â€“34. <i>Hearing Research</i> , 1997, 103, 69-74.	0.9	62
20	Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies. <i>Blood Cancer Discovery</i> , 2021, 2, 568-576.	2.6	62
21	Association of Immune Marker Changes With Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma. <i>JAMA Oncology</i> , 2019, 5, 1293.	3.4	57
22	Ear and Hearing Problems in Turner's Syndrome. <i>Acta Oto-Laryngologica</i> , 2003, 123, 253-257.	0.3	54
23	Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e422-e432.	2.2	50
24	COVID-19 Infections and Clinical Outcomes in Patients with Multiple Myeloma in New York City: A Cohort Study from Five Academic Centers. <i>Blood Cancer Discovery</i> , 2020, 1, 234-243.	2.6	46
25	Patients with polycythemia vera have worst impairment of quality of life among patients with newly diagnosed myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2013, 54, 2226-2230.	0.6	43
26	Characterization of hearing in an X,0 â€”Turner mouseâ€™. <i>Hearing Research</i> , 2000, 143, 182-188.	0.9	41
27	Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma. <i>JAMA Oncology</i> , 2020, 6, 425.	3.4	41
28	Accelerated single cell seeding in relapsed multiple myeloma. <i>Nature Communications</i> , 2020, 11, 3617.	5.8	41
29	Leukemic transformation in myeloproliferative neoplasms: Therapy-related or unrelated?. <i>Best Practice and Research in Clinical Haematology</i> , 2014, 27, 141-153.	0.7	40
30	Comprehensive detection of recurring genomic abnormalities: a targeted sequencing approach for multiple myeloma. <i>Blood Cancer Journal</i> , 2019, 9, 101.	2.8	40
31	Comparison of MALDIâ€”TOF mass spectrometry analysis of peripheral blood and bone marrowâ€”based flow cytometry for tracking measurable residual disease in patients with multiple myeloma. <i>British Journal of Haematology</i> , 2020, 189, 904-907.	1.2	40
32	Synkinesis in Bell's palsy in a randomised controlled trial. <i>Clinical Otolaryngology</i> , 2017, 42, 673-680.	0.6	38
33	Multiple Myeloma and Its Precursor Disease Among Firefighters Exposed to the World Trade Center Disaster. <i>JAMA Oncology</i> , 2018, 4, 821.	3.4	38
34	Baseline mutational patterns and sustained MRD negativity in patients with high-risk smoldering myeloma. <i>Blood Advances</i> , 2017, 1, 1911-1918.	2.5	37
35	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2019, 134, 862-862.	0.6	34
36	Risk of infections in patients with myeloproliferative neoplasmsâ€”a population-based cohort study of 8363 patients. <i>Leukemia</i> , 2021, 35, 476-484.	3.3	32

#	ARTICLE	IF	CITATIONS
37	Short-term results from seventy-six patients receiving a bone-anchored hearing implant installed with a novel minimally invasive surgery technique. <i>Clinical Otolaryngology</i> , 2017, 42, 1043-1048.	0.6	31
38	Peripheral facial palsy: Speech, communication and oral motor function. <i>European Annals of Otorhinolaryngology, Head and Neck Diseases</i> , 2017, 134, 27-31.	0.4	31
39	MRD Testing in Multiple Myeloma: The Main Future Driver for Modern Tailored Treatment. <i>Seminars in Hematology</i> , 2018, 55, 44-50.	1.8	31
40	Molecular underpinnings of clinical disparity patterns in African American vs. Caucasian American multiple myeloma patients. <i>Blood Cancer Journal</i> , 2019, 9, 15.	2.8	30
41	Incidence of myeloproliferative neoplasms – trends by subgroup and age in a population-based study in Sweden. <i>Journal of Internal Medicine</i> , 2020, 287, 448-454.	2.7	30
42	Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxis. <i>British Journal of Haematology</i> , 2022, 196, 105-109.	1.2	30
43	Copy number signatures predict chromothripsis and clinical outcomes in newly diagnosed multiple myeloma. <i>Nature Communications</i> , 2021, 12, 5172.	5.8	27
44	Survival in multiple myeloma patients who develop second malignancies: a population-based cohort study. <i>Haematologica</i> , 2016, 101, e145-e148.	1.7	26
45	Baseline identification of clonal V(D)J sequences for DNA-based minimal residual disease detection in multiple myeloma. <i>PLoS ONE</i> , 2019, 14, e0211600.	1.1	24
46	Phase I First-in-Class Trial of MCarH109, a G Protein Coupled Receptor Class C Group 5 Member D (GPCR5D) Targeted CAR T Cell Therapy in Patients with Relapsed or Refractory Multiple Myeloma. <i>Blood</i> , 2021, 138, 827-827.	0.6	23
47	Stability and uniqueness of clonal immunoglobulin CDR3 sequences for MRD tracking in multiple myeloma. <i>American Journal of Hematology</i> , 2019, 94, 1364-1373.	2.0	22
48	History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study. <i>Annals of Hematology</i> , 2017, 96, 261-269.	0.8	20
49	Inner ear morphology in CBA/Ca and C57BL/6J mice in relationship to noise, age and phenotype. <i>European Archives of Oto-Rhino-Laryngology</i> , 1993, 250, 257-64.	0.8	19
50	Routine Evaluation of Minimal Residual Disease in Myeloma Using Next-Generation Sequencing Clonality Testing. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 181-199.	1.2	19
51	Circulating Adiponectin Levels Differ Between Patients with Multiple Myeloma and its Precursor Disease. <i>Obesity</i> , 2017, 25, 1317-1320.	1.5	17
52	Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 198-200.	0.2	17
53	The target cell response to cytokines governs the autoreactive T cell repertoire in the pancreas of NOD mice. <i>Diabetologia</i> , 2009, 52, 299-305.	2.9	16
54	Incidence and risk factors for suicide and attempted suicide following a diagnosis of hematological malignancy. <i>Cancer Medicine</i> , 2015, 4, 147-154.	1.3	16

#	ARTICLE	IF	CITATIONS
55	Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 1816-1821.	1.9	15
56	Infants under the age of six months with acute mastoiditis. A descriptive study of 15 years in Sweden. <i>International Journal of Pediatric Otorhinolaryngology</i> , 2014, 78, 1119-1122.	0.4	15
57	The impact of prior malignancies on second malignancies and survival in MM patients: a population-based study. <i>Blood Advances</i> , 2017, 1, 2392-2398.	2.5	15
58	Hemoglobin concentration and risk of arterial and venous thrombosis in 1.5 million Swedish and Danish blood donors. <i>Thrombosis Research</i> , 2020, 186, 86-92.	0.8	14
59	The Influence of Prenatal Gamma Irradiation on the Ageing of the Cochlea. <i>Acta Oto-Laryngologica</i> , 1989, 108, 414-423.	0.3	12
60	Blood donation and risk of polycythemia vera. <i>Transfusion</i> , 2016, 56, 1622-1627.	0.8	12
61	Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms. <i>Annals of Internal Medicine</i> , 2018, 169, 268.	2.0	12
62	Risk of Arterial and Venous Thrombosis in 11,155 Patients with Myeloproliferative Neoplasms and 44,620 Matched Controls; A Population-Based Study. <i>Blood</i> , 2014, 124, 632-632.	0.6	11
63	Inner Ear Content of Glycosaminoglycans as Shown by Monoclonal Antibodies. <i>Acta Oto-Laryngologica</i> , 1996, 116, 25-32.	0.3	10
64	Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m ²) in combination with lenalidomide and dexamethasone. <i>American Journal of Hematology</i> , 2021, 96, E193-E196.	2.0	10
65	Screening for Monoclonal Gammopathy of Undetermined Significance: A Population-Based Randomized Clinical Trial. First Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study. <i>Blood</i> , 2021, 138, 156-156.	0.6	10
66	The Pre-and Postnatal Maturation of the Epithelium in the Endolymphatic Sac: An Electron Microscopic Survey. <i>Acta Oto-Laryngologica</i> , 1988, 105, 303-311.	0.3	9
67	Self-reported fertility in long-term survivors of acute myeloid leukemia. <i>Annals of Hematology</i> , 2014, 93, 1491-1498.	0.8	9
68	Dysregulation of shelterin factors coupled with telomere shortening in Philadelphia chromosome negative myeloproliferative neoplasms. <i>Haematologica</i> , 2015, 100, e402-e405.	1.7	9
69	Baseline VDJ clonotype detection using a targeted sequencing NGS assay: allowing for subsequent MRD assessment. <i>Blood Cancer Journal</i> , 2020, 10, 76.	2.8	9
70	The Development of the Endolymphatic Duct and Sac: A Light Microscopical Study. <i>Acta Oto-Laryngologica</i> , 1987, 104, 406-416.	0.3	8
71	Presence of Glycosaminoglycans in the Endolymphatic Sac. <i>Acta Oto-Laryngologica</i> , 1997, 117, 518-522.	0.3	8
72	Pathology of the Cochlea Following a Spontaneous Mutation in DBA/2 Mice. <i>Acta Oto-Laryngologica</i> , 1997, 117, 689-695.	0.3	8

#	ARTICLE	IF	CITATIONS
73	Survival in patients with familial and sporadic myeloproliferative neoplasms. <i>Blood</i> , 2015, 125, 3665-3666.	0.6	8
74	Cumulative exposure to melphalan chemotherapy and subsequent risk of developing acute myeloid leukemia and myelodysplastic syndromes in patients with multiple myeloma. <i>European Journal of Haematology</i> , 2021, 107, 275-282.	1.1	8
75	Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1394-1401.	2.0	8
76	Prevalence of Smoldering Multiple Myeloma: Results from the Iceland Screens, Treats, or Prevents Multiple Myeloma (iStopMM) Study. <i>Blood</i> , 2021, 138, 151-151.	0.6	8
77	Exploring Alternative Dosing Regimens of Single-Agent Belantamab Mafodotin on Safety and Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: DREAMM-14. <i>Blood</i> , 2021, 138, 1645-1645.	0.6	8
78	Genomic profiling of multiple myeloma: New insights and modern technologies. <i>Best Practice and Research in Clinical Haematology</i> , 2020, 33, 101153.	0.7	7
79	Using MALDI-TOF mass spectrometry in peripheral blood for the follow up of newly diagnosed multiple myeloma patients treated with daratumumab-based combination therapy. <i>Clinica Chimica Acta</i> , 2021, 516, 136-141.	0.5	7
80	VTE Rates and Safety Analysis of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Lenalidomide-Dexamethasone (KRd) with or without Rivaroxaban Prophylaxis. <i>Blood</i> , 2019, 134, 1835-1835.	0.6	7
81	Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience. <i>Blood</i> , 2021, 138, 1644-1644.	0.6	7
82	Monoclonal gammopathy of undetermined significance and COVID-19: a population-based cohort study. <i>Blood Cancer Journal</i> , 2021, 11, 191.	2.8	7
83	Nutrition perceptions, needs and practices among patients with plasma cell disorders. <i>Blood Cancer Journal</i> , 2022, 12, 70.	2.8	7
84	Structure and Function of the Adult Cochlea Following Prenatal Irradiation. <i>Acta Oto-Laryngologica</i> , 1985, 100, 4-31.	0.3	6
85	Autoimmune disease is associated with a lower risk of progression in monoclonal gammopathy of undetermined significance. <i>European Journal of Haematology</i> , 2021, 106, 380-388.	1.1	6
86	Degeneration Patterns of Actin Distribution in the Organ of Corti in Two Genotypes of Mice. <i>Orl</i> , 1995, 57, 1-4.	0.6	5
87	Suicide in multiple myeloma and acute myeloid leukaemia. <i>Annals of Oncology</i> , 2007, 18, 1122-1123.	0.6	5
88	Initial Whole-Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. <i>Clinical Cancer Research</i> , 2021, 27, 2111-2118.	3.2	5
89	Congenital Malformation of the Inner Ear and Recurrent Meningitis. <i>Orl</i> , 1996, 58, 333-337.	0.6	4
90	Diabetes mellitus and risk of plasma cell and lymphoproliferative disorders in 94,579 cases and 368,348 matched controls. <i>Haematologica</i> , 2022, 107, 284-286.	1.7	4

#	ARTICLE	IF	CITATIONS
91	Bone Marrow-Based and Longitudinal Blood-Based MRD Tracking in Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (DKRd): A Correlative and Clinical Phase II Study. <i>Blood</i> , 2018, 132, 3281-3281.	0.6	4
92	Depth of Response and Outcomes in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 4619-4619.	0.6	4
93	Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience. <i>American Journal of Hematology</i> , 2022, 97, .	2.0	4
94	African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8045-8045.	0.8	4
95	Expression of glycoconjugates in the mouse inner ear after prenatal irradiation. <i>European Archives of Oto-Rhino-Laryngology</i> , 1992, 249, 134-9.	0.8	3
96	Family history of venous thromboembolism is associated with increased risk for thrombosis in multiple myeloma: a population-based study. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 962-964.	1.9	3
97	Capture Rate of the Adaptive Next Generation Sequencing VDJ Assay in Multiple Myeloma. <i>Blood</i> , 2018, 132, 3184-3184.	0.6	3
98	No Risk of Arterial or Venous Thrombosis in Monoclonal Gammopathy of Undetermined Significance: Results from a Population-Based Study. <i>Blood</i> , 2015, 126, 4252-4252.	0.6	3
99	Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS8073-TPS8073.	0.8	3
100	Myeloma developing regimens using genomics (MyDRUG) trial: Results from the RAS mutation targeting arm.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8055-8055.	0.8	3
101	Endolymphatic Sac Morphology following Long-Term Kanamycin Intoxication. <i>Orl</i> , 1990, 52, 1-9.	0.6	2
102	MRD-Response Driven Phase I/II Study for Newly Diagnosed Multiple Myeloma Patients Using Higher Doses of Twice-Weekly Carfilzomib (45 and 56 mg/m ²) in Combination with Lenalidomide and Dexamethasone. <i>Blood</i> , 2018, 132, 1983-1983.	0.6	2
103	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Multiple Myeloma Patients Treated with Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2019, 134, 3127-3127.	0.6	2
104	MALDI-TOF Mass Spectrometry in Serum for the Follow-up of Newly Diagnosed Multiple Myeloma Patients Treated with Daratumumab-Based Combination Therapy. <i>Blood</i> , 2019, 134, 4377-4377.	0.6	2
105	The Success Story of Targeted Therapy In Chronic Myeloid Leukemia: A Population-Based Study of 3,173 Patients Diagnosed In Sweden 1973-2008. <i>Blood</i> , 2010, 116, 205-205.	0.6	2
106	Multiple Myeloma and Infections: A Population-Based Study Based On 9,610 Multiple Myeloma Patients. <i>Blood</i> , 2012, 120, 945-945.	0.6	2
107	Patterns of Infectious Morbidity in Patients with Waldenström's Macroglobulinaemia/Lymphoplasmacytic Lymphoma: A Population-Based Study. <i>Blood</i> , 2014, 124, 3350-3350.	0.6	2
108	Defining New Reference Intervals for Serum Free Light Chains in Individuals with Reduced Kidney Function: Results of the Population- Based on Iceland Screens Treats or Prevents Multiple Myeloma (iStopMM) Study. <i>Blood</i> , 2021, 138, 542-542.	0.6	2

#	ARTICLE	IF	CITATIONS
109	Copy Number Signatures Predict Chromothripsis and Poor Clinical Outcome in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2020, 136, 52-53.	0.6	2
110	Association of Patient Activity Bioprofiles with Hrql and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2020, 136, 26-28.	0.6	2
111	Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 2160-2166.	3.2	2
112	Turnover of sulphated macromolecules in the murine endolymphatic sac after long-term kanamycin treatment. <i>American Journal of Otolaryngology - Head and Neck Medicine and Surgery</i> , 1989, 10, 386-392.	0.6	1
113	Influence of Prenatal Irradiation on Second Generation Mice. <i>Acta Oto-Laryngologica</i> , 1995, 115, 638-642.	0.3	1
114	Continuous Mobile Wearable Bio-Monitoring of Newly Diagnosed Multiple Myeloma Patients Undergoing Initial Chemotherapy. <i>Blood</i> , 2018, 132, 4751-4751.	0.6	1
115	Risk of Progression in Monoclonal Gammopathy of Undetermined Significance (MGUS): Results from a Population-Based Screening Study. <i>Blood</i> , 2016, 128, 5650-5650.	0.6	1
116	Whole Genome Sequencing of Extramedullary Myeloma Autopsy Tumors Reveals a Genomic Portrait at Culmination of Clonal Convergence. <i>Blood</i> , 2018, 132, 3169-3169.	0.6	1
117	A Pilot Plant-Based Dietary Intervention in Overweight and Obese Patients with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma- the Nutrition Prevention (NUTRIVENTION) Study. <i>Blood</i> , 2021, 138, 4759-4759.	0.6	1
118	Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms. <i>Blood</i> , 2021, 138, 3271-3271.	0.6	1
119	VRd Versus KRd Safety Profiles in Newly Diagnosed Multiple Myeloma Patients Using Real-World Evidence Data from a Single Institution: VRd Has High Rates of Chronic Neuropathy, and KRd Has Low Rates of Cardiopulmonary or Renal Toxicities When Using Optimized IV Fluid Management Coupled with Baseline Cardiac Workup. <i>Blood</i> , 2020, 136, 37-38.	0.6	1
120	Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2020, 136, 7-7.	0.6	1
121	The Genomic Complexity of Multiple Myeloma Precursor Disease Can be Predicted Using Copy Number Signatures on Targeted Sequencing and SNP Array Data. <i>Blood</i> , 2020, 136, 10-10.	0.6	1
122	Evaluating serum-free light chain ratio as a biomarker for multiple myeloma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8047-8047.	0.8	1
123	Ixazomib and dexamethasone in high risk smoldering multiple myeloma: a clinical and correlative pilot study. <i>Leukemia and Lymphoma</i> , 2022, 63, 2760-2761.	0.6	1
124	A scanning electron microscopic study of vestibular organ malformation following prenatal gamma irradiation. <i>Archives of Oto-rhino-laryngology</i> , 1987, 244, 229-235.	0.5	0
125	ACUTE TYMPANIC MEMBRANE PERFORATIONS HEAL WITHOUT SIGNIFICANT LOSS OF STRENGTH. , 2007, , .		0
126	Patterns of Survival and Causes of Death In 9,384 Patients with Myeloproliferative Neoplasms Diagnosed In Sweden Between 1973 and 2008. <i>Blood</i> , 2010, 116, 3071-3071.	0.6	0

#	ARTICLE	IF	CITATIONS
127	Risk and Cause of Death in 9,563 Patients Diagnosed with Myeloproliferative Neoplasms in Sweden Between 1973 and 2005,. Blood, 2011, 118, 3855-3855.	0.6	0
128	A Population-Based Study of Incidence of Myeloproliferative Neoplasms in Sweden Between 2000 and 2012. Blood, 2015, 126, 1605-1605.	0.6	0
129	The Impact of Prior Malignancies on Second Malignancies and Survival in MM Patients: A Population-Based Study. Blood, 2016, 128, 3246-3246.	0.6	0
130	Treatment Outcomes in Monoclonal Immunoglobulin Deposition Disease (MIDD): A Two Center Experience. Blood, 2018, 132, 5591-5591.	0.6	0
131	V(D)J Sequence Capture for DNA-Based Minimal Residual Disease Detection in Multiple Myeloma. Blood, 2018, 132, 4444-4444.	0.6	0
132	Next-Generation Sequencing-Based Assay Shows High Clonal Characterization Success Rate for Plasma Cell Neoplasms, and Concordance with Flow Cytometry in Minimal Residual Disease Detection. Blood, 2018, 132, 4475-4475.	0.6	0
133	Mytype: A Capture Based Sequencing Approach to Detect Somatic Mutations, Copy Number Changes and IGH Translocations in Multiple Myeloma. Blood, 2018, 132, 5588-5588.	0.6	0
134	Comparison of MALDI-TOF Mass Spectrometry Analysis of Peripheral Blood and Bone Marrow Based Flow Cytometry for Tracking Measurable Residual Disease (MRD) in Patients with Multiple Myeloma. Blood, 2019, 134, 3060-3060.	0.6	0
135	An Observational, Retrospective Analysis of Retreatment with Carfilzomib in the Management of Patients with Multiple Myeloma. Blood, 2019, 134, 5554-5554.	0.6	0
136	Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from the Population-Based Iceland Screens Treats or Prevents Multiple Myeloma Study (iStopMM). Blood, 2021, 138, 154-154.	0.6	0
137	Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures. Blood, 2021, 138, 4762-4762.	0.6	0
138	Estimating Selection Bias in Previous Monoclonal Gammopathy of Undetermined Significance Research - the Importance of Screening: Results from the Population-Based Screening Study Iceland Screens, Treats or Prevents Multiple Myeloma (iStopMM). Blood, 2021, 138, 1618-1618.	0.6	0
139	Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. Blood, 2020, 136, 18-19.	0.6	0
140	Diabetes Mellitus and Risk of Plasma Cell and Lymphoproliferative Disorders: A Population Based Study Including 94,579 Cases and 368,348 Matched Controls. Blood, 2020, 136, 44-45.	0.6	0
141	A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study). Blood, 2020, 136, 8-10.	0.6	0
142	Initial Whole Genome Sequencing of Plasma Cell Neoplasms in First Responders and Recovery Workers Exposed to the World Trade Center Attack of September 11, 2001. Blood, 2020, 136, 50-51.	0.6	0
143	Embryonic and postnatal development of endolymphatic sac blood vessels. The American Journal of Otolaryngology, 1990, 11, 90-4.	0.4	0
144	Correlation between auditory brainstem recordings and morphology as seen through the scanning electron microscope. Scanning Microscopy, 1988, 2, 1725-37.	0.3	0

#	ARTICLE	IF	CITATIONS
145	Labeling of the glucocorticoid receptor and Na,K-ATPase in a rat otitis media model. The American Journal of Otology, 2000, 21, 36-41.	0.4	0
146	Clinical efficacy of daratumumab (DARA)-based second line therapy after DARA-containing and DARA-free induction therapies in multiple myeloma: A single center experience.. Journal of Clinical Oncology, 2022, 40, e20005-e20005.	0.8	0